Literature DB >> 17205243

Inhaled nitric oxide therapy during the transport of neonates with persistent pulmonary hypertension or severe hypoxic respiratory failure.

Calvin G Lowe1, Johnn G Trautwein.   

Abstract

Our aim was to determine whether starting inhaled nitric oxide (iNO) on critically ill neonates with severe hypoxemic respiratory failure and/or persistent pulmonary hypertension (PPH), at a referring hospital at the start of transport, decreases the need for extracorporeal membrane oxygenation (ECMO), lessens the number of hospital days and improves survival in comparison with those patients who were started on iNO only at the receiving facility. The study was a retrospective review of 94 charts of neonates that had iNO initiated by the transport team at a referring hospital or only at the tertiary neonatal intensive care unit (NICU) of the receiving hospital. Data collected included demographics, mode of transport, total number of hospital days, days on inhaled nitric oxide and ECMO use. Of the 94 patients, 88 were included. Of these, 60 were started on iNO at the referring facility (Field-iNO) and 28 were started at the receiving NICU (CHLA-iNO). All patients survived transport to the receiving NICU. Death rates and ECMO use were similar in both groups. Overall, patients who died were younger and had lower birth weights and Apgar scores. For all surviving patients who did not require ECMO, the length of total hospital stay (median days 22 versus 38, P = 0.018), and the length of the hospital stay at the receiving hospital (median days 18 versus 29, P = 0.006), were significantly shorter for the Field-iNO patients than for the CHLA-iNO patients, respectively. Earlier initiation of iNO may decrease length of hospital stay in surviving neonates with PPH not requiring ECMO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205243     DOI: 10.1007/s00431-006-0374-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

Review 1.  Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia.

Authors:  J P Kinsella; S H Abman
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

2.  Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization.

Authors:  S R Hintz; D M Suttner; A M Sheehan; W D Rhine; K P Van Meurs
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

3.  Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn.

Authors:  H Christou; L J Van Marter; D L Wessel; E N Allred; J W Kane; J E Thompson; A R Stark; S Kourembanas
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

4.  Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn.

Authors:  D L Wessel; I Adatia; L J Van Marter; J E Thompson; J W Kane; A R Stark; S Kourembanas
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

5.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

6.  Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group.

Authors:  D Davidson; E S Barefield; J Kattwinkel; G Dudell; M Damask; R Straube; J Rhines; C T Chang
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

7.  Transfer of critically ill patients with inhaled nitric oxide.

Authors:  A P Goldman; R C Tasker; P Cook; D J Macrae
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

8.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group.

Authors:  R H Clark; T J Kueser; M W Walker; W M Southgate; J L Huckaby; J A Perez; B J Roy; M Keszler; J P Kinsella
Journal:  N Engl J Med       Date:  2000-02-17       Impact factor: 91.245

9.  Inhaled nitric oxide for avoidance of extracorporeal membrane oxygenation in the treatment of severe persistent pulmonary hypertension of the newborn.

Authors:  W Muller; W Kachel; P Lasch; V Varnholt; S A Konig
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

10.  A portable nitric oxide scavenging system designed for use on neonatal transport.

Authors:  J S Dhillon; J B Kronick; N C Singh; C C Johnson
Journal:  Crit Care Med       Date:  1996-06       Impact factor: 7.598

View more
  2 in total

1.  The Burden of Hypoxic Respiratory Failure in Preterm and Term/Near-term Infants in the United States 2011-2015.

Authors:  Shivani Pandya; Onur Baser; George J Wan; Belinda Lovelace; Jim Potenziano; An T Pham; Xingyue Huang; Li Wang
Journal:  J Health Econ Outcomes Res       Date:  2019-06-19

2.  Nitric oxide synthases in infants and children with pulmonary hypertension and congenital heart disease.

Authors:  Thomas Hoehn; Brigitte Stiller; Allan R McPhaden; Roger M Wadsworth
Journal:  Respir Res       Date:  2009-11-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.